Emma Gilthorpe resigns as Royal Mail chief executive after just a year
The chief executive of Royal Mail has left after just over a year, weeks after the delivery company's owner was sold for £3.6bn to a Czech billionaire.
Emma Gilthorpe, who joined from Heathrow airport in May 2024, left the company on Thursday, and will be replaced on an interim basis by the chief operating officer, Alistair Cochrane, with immediate effect, the Guardian has learned.
Daniel Křetínský completed a deal to buy International Distribution Services (IDS), the owner of the 509-year-old Royal Mail, in April.
A group of existing IDS non-executive directors, including the chair, Keith Williams, resigned earlier this month. However, the company had made no mention of Gilthorpe's future after the deal.
She had been the chief operating officer at Heathrow airport since 2020, and joined Royal Mail in a newly created role under Martin Seidenberg, who is chief executive of IDS. Gilthorpe had also held positions in the telecoms industry, with BT and Cable & Wireless.
She said: 'I will always be incredibly proud to have led Royal Mail … I look forward to seeing Royal Mail continue to transform in the years ahead, ensuring a stronger and more sustainable future for this great British company.'
Cochrane joined Royal Mail in 2023 from the delivery company Whistl, where he was chief executive. He has also held senior roles at TNT Express and Parcelforce Worldwide.
He becomes Royal Mail's fourth boss in three years. Seidenberg, who had responsibility for the division before Gilthorpe was installed, replaced Simon Thompson, who stepped down in 2023 after only two years following an acrimonious tussle with unions.
Thompson had become the latest in a line of executives to clash with unions as they attempted to overhaul the company after its privatisation in 2013.
Seidenberg said: 'Emma has worked tirelessly to drive forward Royal Mail's transformation, and I would like to extend my personal thanks to her for the significant contribution she has made to the company.'
He added: 'Alistair Cochrane is an exceptional leader and brings significant experience to his new role from across the logistics industry, and from his time with us at both Royal Mail and Parcelforce.'
In May, the industry regulator, Ofcom, launched an investigation into Royal Mail's quality of service after almost a quarter of first-class post last year arrived late. The target is for 93% of first-class items to arrive within one working day.
Consumers and businesses have lamented the standard of service, complaining about delivery delays and higher stamp prices. In April, the price of a first-class stamp rose by 5p, or 3%, to £1.70 – the sixth increase in little more than three years.
Ofcom has been examining whether to relax rules on Royal Mail's service, and has proposed allowing it to only deliver second-class letters on alternate weekdays and not on Saturdays, with first-class post remaining six days a week.
Křetínský's EP Group clinched the IDS deal after a long-running UK government review of the national security considerations approved the deal.
The Conservative former trade policy minister Greg Hands was this month appointed as a strategic adviser to EP Group.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Airbus Stock Climbs, Embraer Rallies After Paris Air Show Wins
Dealmaking continued at the 55th Paris Air Show as the showcase of global aerospace technology and economics event headed into day three. Airbus already landed multiple contracts. Brazilian manufacturer Embraer secured a $3.6 billion deal on Wednesday.
Yahoo
an hour ago
- Yahoo
Piper Sandler Reaffirms Overweight Rating on Soleno (SLNO) Driven by Strong VYKAT XR Prospects
Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the 10 biotech stocks screaming a buy now. On June 17, Piper Sandler reiterated an 'Overweight' rating on the stock with a $145 price target. The bullish stance follows positive discussions with a European specialist on the company's VYKAT XR medication for Prader-Willi syndrome (PWS). A scientist in a laboratory examining a microscope in the pursuit of cell therapy discoveries. Piper Sandler consulted a UK-based pediatric endocrinologist to understand the drug better. The specialist indicated she would prescribe the drug as medication for Prader-Willi syndrome (PWS) to all eligible patients upon approval. Soleno Therapeutics' edge with the drug stems from the fact that other PWS treatments are in the early stages of development. Piper Sandler believes VYKAT XT represents significant potential as the first approved treatment specifically addressing PWS, a condition. The biotech company plans to file a Marketing Authorization Application for VYKAT XR in the second quarter. It's also pursuing regulatory approval in Europe as it plans to fill with the European Medicines agency. Following regulatory approvals, Soleno Therapeutics Palms will launch the drug in the first quarter of 2026. Soleno Therapeutics is a biopharmaceutical company that develops and commercializes novel treatments for rare diseases. Their lead product, diazoxide choline extended-release tablets (DCCR), is being developed for Prader-Willi syndrome (PWS), specifically to address hyperphagia (excessive hunger). While we acknowledge the potential of SLNO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Bloomberg
2 hours ago
- Bloomberg
Plunging UK Retail Sales Deepen Concern About Broader Slowdown
A dramatic drop in UK retail sales is raising fresh questions about the sustainability of Britain's recent growth spurt and Prime Minister Keir Starmer's plans to use it to restore controversial benefit cuts. The volume of goods sold online and in shops dropped 2.7% in May, the Office for National Statistics said on Friday. Not only was that the sharpest decline since December 2023, it was enough to wipe out the combined gains over the previous four months of the year. Economists had expected retail sales to fall only 0.5% last month.
